| A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) (NCT03217812) | Janssen Research & Development, LLC | 2017-11-23 |
| A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma (NCT03357952) | Janssen Research & Development, LLC | 2017-11-16 |
| Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) (NCT03340883) | Chinook Therapeutics, Inc. | 2017-11-15 |
| A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma (NCT03312530) | Hoffmann-La Roche | 2017-11-13 |
| Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma (NCT03190525) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2017-11-13 |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) (NCT03173092) | Takeda | 2017-11-13 |
| A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (NCT03215524) | Canadian Myeloma Research Group | 2017-10-25 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (NCT04287660) | The First Affiliated Hospital of Soochow University | 2017-10-19 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL (NCT03019666) | Masonic Cancer Center, University of Minnesota | 2017-10-18 |
| A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT03215030) | Teva Branded Pharmaceutical Products R&D LLC | 2017-10-04 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma (NCT03168100) | University of Arkansas | 2017-10-01 |
| Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma (NCT03283046) | M.D. Anderson Cancer Center | 2017-10-01 |
| MUK Nine b: OPTIMUM Treatment Protocol (NCT03188172) | University of Leeds | 2017-09-28 |
| MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma (NCT03218163) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-09-27 |
| A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma (NCT03290950) | Memorial Sloan Kettering Cancer Center | 2017-09-25 |
| Myeloma Registry Platform (MYRIAM) (NCT03308474) | iOMEDICO AG | 2017-09-25 |
| P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) (NCT03288493) | Poseida Therapeutics, Inc. | 2017-09-20 |
| Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen (NCT03595800) | Institut Paoli-Calmettes | 2017-09-19 |
| Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (NCT03275103) | Genentech, Inc. | 2017-09-19 |
| Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma (NCT03262389) | Michael C Roarke, MD | 2017-09-19 |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment (NCT02951117) | AbbVie | 2017-08-31 |
| Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation (NCT03276481) | Memorial Sloan Kettering Cancer Center | 2017-08-28 |
| Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT (NCT03233776) | Radboud University Medical Center | 2017-08-21 |
| Study of bb21217 in Multiple Myeloma (NCT03274219) | 2seventy bio | 2017-08-16 |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone (NCT03104842) | Universitätsklinikum Hamburg-Eppendorf | 2017-08-15 |
| A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT03242889) | Janssen Pharmaceutical K.K. | 2017-08-10 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) (NCT03221634) | Merck Sharp & Dohme LLC | 2017-08-01 |
| Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) (NCT03188536) | Takeda | 2017-07-26 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma (NCT03127761) | Center for International Blood and Marrow Transplant Research | 2017-07-25 |
| Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma (NCT03143985) | Koen van Besien | 2017-07-21 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (NCT02780609) | H. Lee Moffitt Cancer Center and Research Institute | 2017-07-20 |
| Bendamustine and Melphalan in Myeloma (NCT03187223) | Insel Gruppe AG, University Hospital Bern | 2017-07-20 |
| Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (NCT02969837) | University of Chicago | 2017-07-10 |
| 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (NCT03004287) | University of Arkansas | 2017-07-01 |
| Lonquek for Autologous Stem Cell Mobilization (NCT02488382) | Sheba Medical Center | 2017-07-01 |
| Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients (NCT03001804) | Celgene | 2017-06-30 |
| Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma (NCT03068351) | Hoffmann-La Roche | 2017-06-26 |
| A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT03091257) | Massachusetts General Hospital | 2017-06-21 |
| Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients (NCT03409692) | Mario Boccadoro | 2017-06-14 |
| Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement (NCT02952573) | University Health Network, Toronto | 2017-06-13 |
| To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma (NCT02732925) | Royal National Orthopaedic Hospital NHS Trust | 2017-06-09 |
| Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (NCT03015922) | University of Leeds | 2017-06-05 |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat (NCT02802163) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-01 |
| Observational Study of Home Administration of Carfilzomib (NCT04621955) | Universitaire Ziekenhuizen KU Leuven | 2017-06-01 |
| Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma (NCT03173430) | Abramson Cancer Center at Penn Medicine | 2017-05-27 |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (NCT03110562) | Karyopharm Therapeutics Inc | 2017-05-24 |
| Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. (NCT03225417) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2017-05-16 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide (NCT03117361) | PharmaMar | 2017-05-08 |
| Multiple Myeloma Patient Registry (NCT03180853) | Janssen Scientific Affairs, LLC | 2017-05-08 |
| APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma (NCT03287804) | Autolus Limited | 2017-05-05 |
| cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study. (NCT03122327) | Peking Union Medical College Hospital | 2017-05-01 |
| Identification of Occupational Exposures in Acute Hematologic Malignancy (NCT03316209) | Centre Hospitalier Intercommunal Creteil | 2017-04-27 |
| ASCT With Nivolumab in Patients With Multiple Myeloma (NCT03292263) | St. Petersburg State Pavlov Medical University | 2017-04-24 |
| Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients (NCT02918695) | Universitaire Ziekenhuizen KU Leuven | 2017-04-07 |
| 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy (NCT03000634) | University of Arkansas | 2017-04-01 |
| A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant (NCT03106324) | Celgene | 2017-03-31 |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (NCT03106428) | MedImmune LLC | 2017-03-29 |
| Cardiovascular Complications of Carfilzomib Treatment (NCT03543579) | University of Athens | 2017-03-23 |
| The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) (NCT03562169) | University of Leeds | 2017-03-20 |
| A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (NCT03000452) | Celgene | 2017-03-14 |
| Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe (NCT03091127) | Amgen | 2017-03-14 |
| Combination Study for High Risk Multiple Myeloma Patients (NCT03104270) | Oncotherapeutics | 2017-03-13 |
| Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy (NCT02891811) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2017-03-10 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma (NCT02978235) | Taiho Oncology, Inc. | 2017-03-01 |
| Quality of Life the Danish Multiple Myeloma Patients (NCT02892383) | Odense University Hospital | 2017-02-27 |
| BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (NCT03070327) | Memorial Sloan Kettering Cancer Center | 2017-02-27 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma (NCT03093168) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 2017-02-15 |
| Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma (NCT02928029) | Bayer | 2017-02-10 |
| Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery (NCT04955808) | National Cancer Institute (NCI) | 2017-02-07 |
| A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients (NCT03110822) | Oncotherapeutics | 2017-02-01 |
| Vaccination With PD-L1 Peptide Against Multiple Myeloma (NCT03042793) | Lene Meldgaard Knudsen | 2017-02-01 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) (NCT02899052) | AbbVie | 2017-01-19 |
| A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) (NCT02955550) | Celularity Incorporated | 2017-01-05 |
| Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma (NCT03023527) | PETHEMA Foundation | 2017-01-01 |
| A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma (NCT03033316) | Enceladus Pharmaceuticals BV | 2017-01-01 |
| Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma (NCT02967276) | University of Campinas, Brazil | 2017-01-01 |
| A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT02963493) | Oncopeptides AB | 2016-12-28 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery (NCT02955043) | University of Wisconsin, Madison | 2016-12-22 |
| Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace (NCT02898064) | University Hospitals of North Midlands NHS Trust | 2016-12-19 |
| Ixazomib Rollover Study (NCT02924272) | Takeda | 2016-12-16 |
| Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant (NCT02716805) | Ludwig Institute for Cancer Research | 2016-12-13 |
| ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma (NCT02757326) | RedHill Biopharma Limited | 2016-12-13 |
| Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) (NCT02906332) | Hackensack Meridian Health | 2016-12-12 |
| Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma (NCT03210753) | National Taiwan University Hospital | 2016-12-01 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Mobile Health Device Study for Myeloma Patients (NCT03006315) | Memorial Sloan Kettering Cancer Center | 2016-12-01 |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma (NCT02756663) | Novartis Pharmaceuticals | 2016-12-01 |
| A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma (NCT02954796) | Seagen Inc. | 2016-12-01 |
| A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma (NCT02951819) | Janssen Scientific Affairs, LLC | 2016-11-09 |
| Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure (NCT03323541) | University Hospital, Brest | 2016-11-03 |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) (NCT02955810) | National University of Ireland, Galway, Ireland | 2016-11-01 |
| Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors (NCT03061305) | Strata Oncology | 2016-11-01 |
| Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (NCT02669615) | Medical College of Wisconsin | 2016-11-01 |